BRKR Bruker Corporation

Bruker Daltonics NBC Detection Corporation today announces that it has received a $0.75 million follow-on Phase II contract award for further research and development into the Autonomous Rapid Facility Chemical Agent Monitor (ARFCAM) from the U.S. Department of Homeland Security. ARFCAM is intended to be the next generation chemical agent monitor for government facilities. Frank Thibodeau, Vice President for NBC Business Development, commented: "This award indicates that Bruker Daltonics has performed well in Phase I and has unique expertise to design and deliver the next-generation technology to help protect our country from the threat of chemical terrorism. This is a challenging program with accelerated timelines and ambitious technical specifications, and we are gratified that the Department of Homeland Security has shown confidence in the ability of Bruker Daltonics to meet these requirements." ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, as well as a developer and provider of nuclear, biological and chemical (NBC) detection systems. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.